Bioscience

Capstone Therapeutics announces continuation of phase 2 clinical trial

March 2, 2010

By Flinn Foundation

[Source: Market Watch] – Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from one of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

The company’s goals for this analysis were to assess AZX100 ongoing safety, to evaluate the quality of the clinical trial dataset in order to guide future studies and to determine whether continuation of the trial would be futile from a statistical perspective.

For more information: Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Keloid Scarring